Articles By Nicola Dalbeth, MBChB, MD, FRACP, FRSNZ

stop sign with remission written on it

Treatment goals in gout: aim for remission!

By Nicola Dalbeth, MBChB, MD, FRACP, FRSNZ

Rheumatologists are used to the concept of disease remission as this is a treatment goal we use for many chronic rheumatic diseases in our clinical practice.

Read Article
equity

Gender equity in academic rheumatology

By Nicola Dalbeth, MBChB, MD, FRACP, FRSNZ

Although almost half of our specialist rheumatology physician workforce is now women, gender inequity in career progression within academic rheumatology is a persistent problem. A recent analysis of the US rheumatology workforce showed that although women were well represented in rheumatology program director and division director leadership roles, women academics were less likely to be full or associate professors, had fewer publications, and received fewer NIH grants.

Read Article
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

Profile picture for user Nicola Dalbeth, MBChB, MD, FRACP, FRSNZ
  • Nicola Dalbeth, MBChB, MD, FRACP, FRSNZ

  • Professor Nicola Dalbeth is a rheumatologist based in Auckland, New Zealand. She leads a research programme focusing on the mechanisms, impact, and treatment of gout. She has been principal investigator of trials for novel therapeutic agents and treatment strategies for gout and has led international initiatives to define central concepts of the disease, including nomenclature, staging, and response to treatment. She was a member of the core oversight team for the 2020 American College of Rheumatology (ACR) Gout Management Guidelines, and a steering committee member on the 2015 ACR/ European Alliance of Associations for Rheumatology gout classification project.

×